The BCR ‐ABL1 transcript type influences response and outcome in Philadelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib

In conclusion, patients with e13a2 transcript had a slower molecular response with inferior response rates to imatinib and a poorer long‐term outcome. This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fajh.24774

Source: American Journal of Hematology - May 1, 2017 Category: Hematology Authors: Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Alessandra Iurlo, Luciano Levato, Francesco Albano, Paolo Vigneri, Elisabetta Abruzzese, Giuseppe Rossi, Serena Rupoli, Francesco Cavazzini, Bruno Martino, Ester Orlandi, Patrizia Pregno, Mario Annu Tags: Research Article Source Type: research